Carotid Atherosclerosis: Clinical Trials

8 trials for Carotid Atherosclerosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 3 withdrawn, 1 active not recruiting, 1 unknown. 8 Phase 2, 3 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 28Completed 3, Withdrawn 3, Active not recruiting 1, Unknown 1
Phase 33Completed 2, Withdrawn 1
Phase 11Withdrawn 1

Follow Carotid Atherosclerosis: new trials by email Literature Review of Carotid Atherosclerosis trials Research Report on Carotid Atherosclerosis

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
SIALIDASE INHIBITION AS ANTIATHEROSCLEROTIC THERAPY
Placebo, Tertinat - Atherosclerosis, Atheroscleroses, Coronary
Phase 2Active not recruitingInstitute for Atherosclerosis Research, Russia12282024-08-292026-07-20
Sonodynamic Therapy Manipulates Atherosclerosis Regression Trial on Patients With Carotid Atherosclerotic Plaques
Sonodynamic therapy (SDT), pseudo-SDT - Carotid Atherosclerosis
Phase 1 / Phase 2WithdrawnFirst Affiliated Hospital of Harbin Medical University2023-09-202023-09-21
Targeted PET/CT and PET/MRI Imaging of Vascular Inflammation
18F-FPPRGD2, Positron emission tomography, Computed tomography - Aortic Aneurysm, Abdominal, Carotid Atherosclerosis
Phase 2WithdrawnStanford University2019-10-012021-05-21
99m Tc-ANNexin-V-128 Scintigraphy for the Identification of Complicated Carotid Atherosclerotic Plaques
99mTc-Annexin-V-128 uptake on scintigraphy - Carotid Atherosclerosis, Atherosclerotic Plaque
Phase 2 / Phase 3WithdrawnAssistance Publique - Hôpitaux de Paris2018-09-012021-10-20
Effects of Lutein Supplementation on Subclinical Atherosclerosis
Placebo, Lutein group, Combination group - Carotid Atherosclerosis, Carotid Intimal Medial Thickness 1
Phase 2 / Phase 3CompletedPeking University1922010-06-012013-07-22
Merck Carotid Atherosclerosis Trial (MK-0000-111)(COMPLETED)
Atorvastatin/niacin extended-release, Atorvastatin, Simvastatin - Carotid Atherosclerosis
Phase 2CompletedMerck Sharp & Dohme LLC1002009-04-012015-09-30
Study of Anti-atherosclerotic Activity of Inflaminat in Asymptomatic Participants With Subclinical Atherosclerosis
Inflaminat, Placebo - Carotid Atherosclerosis
Phase 2UnknownInstitute for Atherosclerosis Research, Russia3002007-09-012012-12-06
ACCULINK for Revascularization of Carotids in High Risk Patients "The ARCHeR Trial"
Over-the-wire & Rapid Exchange ACCULINK (tm) Carotid Stent & ACCUNET (tm) embolic protection system - Carotid Atherosclerosis, Carotid Artery Disease
Phase 2 / Phase 3CompletedAbbott Medical Devices5812000-05-012008-09-12

Narrower conditions

Carotid Artery Diseases (8)  ·  Atherosclerosis (4)  ·  Inflammation (2)  ·  Aortic Aneurysm, Abdominal (1)  ·  Carotid Intimal Medial Thickness 1 (1)  ·  Carotid Stenosis (1)  ·  Coronary Artery Disease (1)  ·  Plaque, Atherosclerotic (1)

Broader conditions

Brain Diseases (8)  ·  Cardiovascular Diseases (8)  ·  Central Nervous System Diseases (8)  ·  Cerebrovascular Disorders (8)  ·  Nervous System Diseases (8)  ·  Vascular Diseases (8)  ·  Arterial Occlusive Diseases (4)  ·  Arteriosclerosis (4)  ·  Pathological Conditions, Signs and Symptoms (3)  ·  Pathologic Processes (2)  ·  Aneurysm (1)  ·  Aortic Aneurysm (1)  ·  Aortic Diseases (1)  ·  Coronary Disease (1)  ·  Heart Diseases (1)

Interventions

Atorvastatin (1)  ·  FPP(RGD)2 (1)  ·  Magnetic Resonance Imaging (1)  ·  Niacin (1)  ·  Positron-Emission Tomography (1)  ·  Simvastatin (1)  ·  Tomography, Emission-Computed (1)

Sponsors

Institute for Atherosclerosis Research, Russia (2)  ·  Abbott Medical Devices (1)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  First Affiliated Hospital of Harbin Medical University (1)  ·  Merck Sharp & Dohme LLC (1)  ·  Peking University (1)  ·  Stanford University (1)

Countries

China (2)  ·  Russia (2)  ·  United States (1)

Top investigators

Alexander N. Orekhov, Prof., PhD, DSci (1)  ·  L. Nelson Hopkins, M.D. (1)  ·  Mark H. Wholey, MD (1)  ·  Michael V. McConnell, MD, MSEE (1)  ·  Xiaoming Lin, M.M. (1)

NIH funding

2017 (1)